| abstract |
The disclosed compound is 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo [27.7.1.14,7.011,15.016,21.020 , 24.030.35] octatriaconta-1 (37), 4 (38), 6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid (formula I), as well as its enantiomers and pharmaceutically acceptable salts. Also disclosed are pharmaceutical compositions based on 17-chloro-5,13,14,22-tetramethyl-28-oxa-2,9-dithia-5,6,12,13,22-pentaazaheptacyclo [27.7.1.14,7.011,15.016, 21.020,24.030,35] octatriaconta-1 (37), 4 (38), 6,11,14,16,18,20,23,29,31,33,35-tridecaene-23-carboxylic acid and its enantiomers and pharmaceutically acceptable salts; and methods of treating cancer using these compounds and compositions. |